Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

TBI based VS chemotherapy based myeloablative conditioning in T cell replete haploidentical transplant

Yanal Alnimer, Murad Aldarayseh, Hiffsa Taj, Zena Chahine, Reinhold Munker, Gregory Monohan, Chaitanya Iragavarapu, Fevzi Yalniz, Ayman Qasrawi

Blood (2025) 146 (Supplement 1): 2442.

https://doi.org/10.1182/blood-2025-2442

Published: 2025

Journal Articles

Beyond age: Genomic features and treatment outcomes in older versus younger adults with Acute Myeloid Leukemia

Hardik Dand, Yanal Alnimer, Rafeh Safdar, Jonah Heidel, Cole Blanford, Chandra Kakarala, Ayman Qasrawi, Gregory Monohan, Reinhold Munker, Chaitanya Iragavarapu, Zena Chahine, Fevzi Yalniz

Blood (2025) 146 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2025-3380

Published: 2025

Journal Articles

Outcomes with liposomal daunorubicin/cytarabine – a single-center experience

Jonah Heidel, Rafeh Safdar, Cole Blanford, Chandra Kakarala, Hardik Dand, Yanal Alnimer, Ayman Qasrawi, Fevzi Yalniz

Blood (2025) 146 (Supplement 1): 6973.

https://doi.org/10.1182/blood-2025-6973

Published: 2025

Journal Articles

Genetic risk model to predict outcomes for AML treated with HMA and venetoclax

Rafeh Safdar, Chandra Kakarala, Jonah Heidel, Cole Blanford, Hardik Dand, Yanal Alnimer, Ayman Qasrawi, Fevzi Yalniz

Blood (2025) 146 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2025-1708

Published: 2025

Journal Articles

Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia

Cole Blanford, Rafeh Safdar, Jonah Heidel, Chandra Kakarala, Hardik Dand, Yanal Alnimer, Ayman Qasrawi, Fevzi Yalniz

Blood (2025) 146 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2025-1729

Published: 2025

Journal Articles

Impact of induction regimen and co-mutations on outcomes in AML with myelodysplasia-related changes

Yanal Alnimer, Rafeh Safdar, Hardik Dand, Cole Blanford, Jonah Heidel, Kakrala Chandra, Zena Chahine, Chaitanya Iragavarapu, Gregory Monohan, Reinhold Munker, Ayman Qasrawi, Fevzi Yalniz

Blood (2025) 146 (Supplement 1): 7034.

https://doi.org/10.1182/blood-2025-7034

Published: 2025

Journal Articles

Efficacy and safety of clia plus venetoclax as salvage therapy for relapsed or refractory Acute Myeloid Leukemia

Sarah Sertich, Brent Harris, Yanal Alnimer, Rafeh Safdar, Gregory Monohan, Zena Chahine, Reinhold Munker, Chaitanya Iragavarapu, Ayman Qasrawi, Fevzi Yalniz

Blood (2025) 146 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2025-3454

Published: 2025

Journal Articles

Appropriate Timing of Allogeneic Bone Marrow Transplant in Patients with Myelodysplastic Syndrome

Yanal Alnimer, Reinhold Munker, Ayman Qasrawi, Gregory Monohan, Chait Iragavarapu, Fevzi Yalniz

Blood (2024) 144 (Supplement 1): 4605.

https://doi.org/10.1182/blood-2024-210157

Published: 2024

Journal Articles

Outcomes of Rituximab and Bendamustine Induction Regimen VS Cytarabine-Based Induction for Patients with Mantle Cell Lymphoma

Yanal Alnimer, Fevzi Yalniz, Gregory Monohan, Reinhold Munker, Ayman Qasrawi, Chait Iragavarapu, Mahmoud Amr

Blood (2024) 144 (Supplement 1): 6320.

https://doi.org/10.1182/blood-2024-211992

Published: 2024

Journal Articles

Efficacy of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm, an Interrupted Time Series Analysis

Yanal Alnimer, Moaath K. Mustafa Ali, Ayman Qasrawi, Fevzi Yalniz, Gregory Monohan, Chait Iragavarapu

Blood (2024) 144 (Supplement 1): 6016.

https://doi.org/10.1182/blood-2024-212229

Published: 2024

Journal Articles

Healthcare Disparities Among Minorities Treated with Venetoclax and Hypomethylating Agents in AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 13305–13306.

https://doi.org/10.1182/blood-2022-171223

Published: 2022

Journal Articles

CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 11745–11746.

https://doi.org/10.1182/blood-2022-171129

Published: 2022

Journal Articles

Real-World Safety and Efficacy of Gemtuzumab Ozogamicin in Relapsed or Refractory AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 11744.

https://doi.org/10.1182/blood-2022-171018

Published: 2022

Journal Articles

Outcomes of FLAG-IDA Versus MEC in Relapsed or Refractory AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 11742–11743.

https://doi.org/10.1182/blood-2022-170836

Published: 2022

Journal Articles

IDH1/2 mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 6335–6336.

https://doi.org/10.1182/blood-2022-170907

Published: 2022

Journal Articles

Back in JAK - Real-World Analysis of JAK mut AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 11812–11813.

https://doi.org/10.1182/blood-2022-171165

Published: 2022

Journal Articles

Efficacy of Hypomethylating Agents with Venetoclax in TP53 mut AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 11842–11843.

https://doi.org/10.1182/blood-2022-170972

Published: 2022

Journal Articles

Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML

Ian M. Bouligny, Graeme Murray, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Keri Maher

Blood (2022) 140 (Supplement 1): 5281–5282.

https://doi.org/10.1182/blood-2022-171063

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

TBI based VS chemotherapy based myeloablative conditioning in T cell replete haploidentical transplant

Beyond age: Genomic features and treatment outcomes in older versus younger adults with Acute Myeloid Leukemia

Outcomes with liposomal daunorubicin/cytarabine – a single-center experience

Genetic risk model to predict outcomes for AML treated with HMA and venetoclax

Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia

Impact of induction regimen and co-mutations on outcomes in AML with myelodysplasia-related changes

Efficacy and safety of clia plus venetoclax as salvage therapy for relapsed or refractory Acute Myeloid Leukemia

Appropriate Timing of Allogeneic Bone Marrow Transplant in Patients with Myelodysplastic Syndrome

Outcomes of Rituximab and Bendamustine Induction Regimen VS Cytarabine-Based Induction for Patients with Mantle Cell Lymphoma

Efficacy of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm, an Interrupted Time Series Analysis

Healthcare Disparities Among Minorities Treated with Venetoclax and Hypomethylating Agents in AML

CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC

Real-World Safety and Efficacy of Gemtuzumab Ozogamicin in Relapsed or Refractory AML

Outcomes of FLAG-IDA Versus MEC in Relapsed or Refractory AML

IDH1/2 mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML

Back in JAK - Real-World Analysis of JAK mut AML

Efficacy of Hypomethylating Agents with Venetoclax in TP53 mut AML

Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only